Insider Trading March 10, 2026

Advanced Flower Capital director increases stake with $73,896 in purchases

Leonard M. Tannenbaum bought 30,270 shares across March 5-6, 2026 as the stock showed recent volatility and the company reported a fourth-quarter earnings miss

By Marcus Reed AFCG
Advanced Flower Capital director increases stake with $73,896 in purchases
AFCG

Director Leonard M. Tannenbaum acquired 30,270 shares of Advanced Flower Capital Inc. (AFCG) in two transactions on March 5 and 6, 2026, spending $73,896 at prices between $2.44 and $2.47. The purchases raise his direct holdings to 5,891,368 shares amid recent share volatility and a significant fourth-quarter earnings shortfall.

Key Points

  • Director Leonard M. Tannenbaum purchased 30,270 shares of AFCG on March 5-6, 2026, spending $73,896 at prices between $2.44 and $2.47.
  • Following the transactions, Tannenbaum directly owns 5,891,368 shares and indirectly owns an additional 399,307 shares through family and a foundation.
  • Advanced Flower Capital reported a Q4 2025 EPS of -$0.12 versus an expected $0.03 and revenue of $5.19 million versus an expected $5.46 million; the stock rose 16% over the past week but remains down 66% over the past year.

Leonard M. Tannenbaum, a director of Advanced Flower Capital Inc. (NASDAQ:AFCG), disclosed purchases of the company's common stock in a Form 4 filing with the Securities and Exchange Commission.

The transactions occurred over two days. On March 5, 2026, Tannenbaum bought 29,000 shares at a weighted average price of $2.44; those shares were acquired in multiple trades with individual prices ranging from $2.37 to $2.49. The following day, March 6, he added 1,270 shares at $2.47 per share. Combined, the two transactions total 30,270 shares for aggregate proceeds of $73,896.

After these purchases, Tannenbaum directly holds 5,891,368 shares of Advanced Flower Capital. He also has indirect holdings of 218,907 shares through his spouse and 180,400 shares held by the Tannenbaum Family Foundation.

The insider buying took place as the company's stock experienced recent movement in public markets. Shares of AFCG rose 16% over the last week, while the stock remains down 66% over the past 12 months. The company is trading at a Price/Book ratio of 0.33. Market commentary included an assessment that the company is trading below its Fair Value, and the firm's market capitalization is reported at $58 million.

Financial results released for the fourth quarter of 2025 painted a challenging picture. Advanced Flower Capital reported earnings per share of -$0.12, missing the anticipated $0.03 by a material margin - a deviation noted as a -500% surprise relative to the expectation. Revenue for the quarter came in at $5.19 million versus expected revenue of $5.46 million. Following the publication of those results, the companys stock experienced a modest uptick in pre-market trading.

The Form 4 filing documents the insider purchases, and the financial results provide context for recent stock moves. The transaction sizes and the discrepancy between headline expectations and reported results highlight the contrasts investors are weighing: director buying on one hand, and an earnings and revenue miss on the other.

For market participants tracking insider activity and small-cap equity performance, the combination of the purchases and the fourth-quarter results will likely remain a data point to monitor as the company reports in future quarters.


Disclosure: The filing information and financial figures presented above are taken from the cited SEC filing and the companys reported quarterly results.

Risks

  • Quarterly performance risk - the company reported a notable earnings and revenue shortfall for Q4 2025, which may weigh on investor sentiment and small-cap equity valuations (impacts equity markets and company investors).
  • Price volatility - the stock has shown sharp short-term movement (a 16% rise in the past week) while remaining down substantially over the year, indicating elevated market volatility for this issuer (impacts traders and market liquidity for small caps).
  • Valuation uncertainty - while the company trades at a Price/Book of 0.33 and has been described as below Fair Value by available analysis, the earnings miss and revenue shortfall introduce uncertainty around near-term upside (impacts valuation-sensitive investors and capital allocation decisions).

More from Insider Trading

NNN REIT CEO Executes $1.49 Million Share Sale as Stock Nears Yearly High Mar 10, 2026 Alpha Teknova CEO Buys $55.8K in Company Stock; Options Awarded Earlier in February Mar 10, 2026 NexPoint Residential CFO Buys 1,000 Shares as Stock Trades Near Year Low Mar 10, 2026 Thermo Fisher CEO Executes $2.06 Million Stock Sale, Exercises Options Mar 10, 2026 Bel Fuse Executive Sells $4.49M in Class B Shares Amid Strong Quarterly Results Mar 10, 2026